EQUITY (Tables)

12 Months Ended

Dec. 31, 2022

Equity [Abstract]

Schedule of Warrants Outstanding and Exercisable

The following table summarizes the status of our warrants and related transactions for each of the presented years:

	Non-Derivative Warrants	Derivative Warrants	Total Number of Warrants	Weighted - Average Exercise Price Per Warrant		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
Balance, January 1, 2021 (1)	36,764,244	42,017,892	78,782,136	$	1.31	$	358,319	5.3
Granted (2)	300,000	—	300,000	$	4.18
Exercised	(7,658,196)	(1,893,537)	(9,551,733)	$	2.26	$	31,343
Cancelled	(250,000)	—	(250,000)	$	1.50
Balance, December 31, 2021	29,156,048	40,124,355	69,280,403	$	1.19	$	142,791	4.7
Granted (2)(3)	1,600,000	19,512,280	21,112,280	$	2.06
Exercised	(82,413)	(4,261,433)	(4,343,846)	$	1.26	$	9,746
Balance, December 31, 2022	30,673,635	55,375,202	86,048,837	$	1.40	$	1,081	3.9
Exercisable, December 31, 2022	28,323,635	55,375,202	83,698,837	$	1.38	$	1,081	3.9

(1)Total number of outstanding warrants reflects the conversion of warrants to acquire Super Voting Shares and Multi-Voting shares into warrants to acquire Subordinate Voting Shares.

(2)The non-derivative warrants were issued for consulting or other services, therefore, these compensatory warrants are accounted for as share-based payment arrangements.

(3)Derivative warrants were issued to the Second Lien Notes Holders and the Acquisition Facility Lender. Refer to Note 14 - Derivative Liabilities for more information.

Schedule of Share-Based Payment Award, Warrants, Valuation Assumptions

The following assumptions were used for the calculations at date of issuance.

	Year Ended December 31,
	2022	2021	2020
Weighted average stock price	$1.74	$4.18	$2.08
Weighted average expected stock price volatility	81%	73%	81%
Expected annual dividend yield	—%	—%	—%
Weighted average expected life of warrants	5.0 years	3.5 years	2.7 years
Weighted average risk-free annual interest rate	3.48%	1.06%	0.35%
Weighted average grant date fair value	$1.13	$2.14	$1.00

Summary of Stock Options Outstanding

The following table summarizes the status of the Company’s options and related transactions for each of the presented years:

	Stock Options	Weighted Average Exercise Price per Stock Options		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life (in Years)
Balance, January 1, 2021	9,573,834	$	2.00	$	36,909	8.4
Granted	11,486,952	$	4.16
Exercised	(291,664)	$	1.90	$	881
Forfeited/expired	(340,002)	$	3.23
Balance, December 31, 2021	20,429,120	$	3.20	$	11,583	8.7
Granted	13,686,806	$	1.95
Exercised	(324,998)	$	1.67	$	620
Forfeited/expired	(3,038,669)	$	4.02
Balance, December 31, 2022	30,752,259	$	2.58	$	—	8.5
Exercisable, December 31, 2022	12,166,594	$	2.46	$	—	7.2

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions

The following assumptions were used for the calculation at date of grant:

	Year Ended December 31,
	2022	2021	2020
Weighted average stock price	$1.95	$4.16	$2.78
Weighted average expected stock price volatility	74.1%	73.0%	80.9%
Expected annual dividend yield	—%	—%	—%
Weighted average expected life	5.7 years	6.0 years	5.9 years
Weighted average risk-free annual interest rate	2.88%	1.23%	0.52%
Weighted average grant date fair value	$1.35	$2.61	$1.78

Summary of Restricted Stock Activity

The following table summarized the status of our restricted stock and related transactions for each presented years:

	Unvested Restricted Stock	Weighted-Average Grant-date Fair Value Price per Restricted Stock		Average Intrinsic Value		Weighted Average Remaining Vesting Term (in Years)
Issued and Outstanding as of January 1, 2021	6,438,186	$	1.85	$	37,728	1.7
Granted	65,398	$	3.66
Vested and Released	(3,424,954)	$	1.63	$	14,251
Cancelled	(219,479)	$	2.45
Issued and Outstanding as of December 31, 2021	2,859,151	$	2.13	$	9,292	1.2
Granted	86,952	$	2.05
Vested and Released	(1,789,784)	$	1.96	$	3,601
Issued and Outstanding as of December 31, 2022	1,156,319	$	2.45	$	881	0.3

Components of Share-based Compensation Expense

As of December 31, 2022, the Company had $19,246 of unrecognized share-based compensation cost related to unvested stock options, restricted stocks and warrants and is expected to be recognized as share-based compensation cost over a weighted average period of 1.4 years as follows:

2023	$	13,485
2024	4,333
2025	1,128
2026	275
2027	25
	$	19,246